Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VVOS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice for failing minimum stockholders' equity requirement and faces potential delisting if unable to regain compliance.
Vivos Therapeutics receives Nasdaq delisting notice over negative stockholders' equity
Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Vivos on April 17 that its negative $1.55 million stockholders' equity fails the $2.5 million minimum requirement. Company has until June 1 to submit a compliance plan or face delisting.
Item 3.01 verify on EDGAR → -
high
Vivos raised $6.8 million in Q1 2026 through warrant exercises ($4.6M) and private placement ($2.25M), which may help restore compliance but doesn't automatically cure the deficiency.
Item 3.01 verify on EDGAR → -
medium
If Nasdaq accepts the compliance plan, Vivos could receive up to 180 days (until October 14, 2026) to regain compliance through additional financing or improved operations.
Item 3.01 verify on EDGAR → -
high
Company warns Nasdaq may reject its plan or that it may fail to regain compliance even with an extension, which would trigger a delisting determination subject to appeal.
Item 3.01 verify on EDGAR →
Summary
Vivos Therapeutics disclosed it received a deficiency notice from Nasdaq on April 17, 2026, after reporting negative stockholders' equity of $1.55 million in its 2025 annual report—well below the required $2.5 million minimum. The notice doesn't immediately delist the stock, but starts a compliance clock: Vivos must submit a remediation plan by June 1, 2026.
If accepted, the company could have until mid-October to fix the problem. Retail holders should understand this is a serious financial warning signal. The company did raise $6.8 million in Q1 2026, which demonstrates some access to capital, but management explicitly cautioned that Nasdaq may reject their plan or that they may fail to achieve compliance even with an extension.
Delisting would severely impact liquidity and likely trigger further stock price decline. Watch for the June 1 deadline and any announcement about whether Nasdaq accepts the compliance plan. Also monitor for additional financing announcements, as the company will likely need to raise more capital or dramatically improve operations to restore positive equity and maintain its listing.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until June 1, 2026, to submit a plan to regain compliance with the Stockholders’ Equity Requirement, which the Company plans to timely submit for the Staff’s consideration. If the plan is accepted, the Staff may grant the Company an extension period of up to 180 calendar days from the date of the deficiency notice (or through October 14, 2026) to regain compliance with the Minimum Stockholders’ Equity Requirement.
Vivos has until June 1, 2026 to submit a compliance plan to Nasdaq. If accepted, the company could receive an extension until October 14, 2026 to regain compliance with the minimum stockholders' equity requirement through additional equity financings or improved operational results.
Added in current filing · verify on EDGAR →
Readers are cautioned that the Staff may not accept the Company’s plan to regain compliance with the Stockholders’ Equity Requirement. Further, even if the Company’s plan of compliance is accepted, the Company may be unable to evidence compliance with the Stockholders’ Equity Requirement during any extension period that the Staff may grant, either through additional equity financings or improved operational results. If the Staff does not accept the Company’s plan or if the Company is unable to regain compliance within any extension period granted by the Staff, the Staff would be required to issue a delisting determination.
The company warns that Nasdaq may reject its compliance plan, or that it may fail to regain compliance even if granted an extension. If unsuccessful, Nasdaq would issue a delisting determination, though the company could request a hearing to stay delisting action. Any delisting would have a material adverse effect on the company.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify